• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Voyager Therapeutics Inc.

    4/23/25 4:02:12 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VYGR alert in real time by email
    DEFA14A 1 vygr-20250423xdefa14a.htm DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

    (Amendment No. )

    ​

    Filed by the Registrant ⌧

    Filed by a Party other than the Registrant ◻

    Check the appropriate box:

    ◻

    Preliminary Proxy Statement

    ◻

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ◻

    Definitive Proxy Statement

    ⌧

    Definitive Additional Materials

    ◻

    Soliciting Material under §240.14a-12

    ​

    ​

    ​

    ​

    ​

    Voyager Therapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)

    ​

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    ​

    Payment of Filing Fee (Check all boxes that apply):

    ⌧

    No fee required

    ◻

    Fee paid previously with preliminary materials

    ◻

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​


    GRAPHIC

    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V71953-P31358 VOYAGER THERAPEUTICS, INC. 75 HAYDEN AVENUE LEXINGTON, MA 02421 VOYAGER THERAPEUTICS, INC. 2025 Annual Meeting June 3, 2025 11:00 AM ET 75 Hayden Avenue Lexington, MA 02421 You invested in VOYAGER THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 20, 2025 to facilitate timely delivery. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Location:Voyager Therapeutics, Inc. 75 Hayden Avenue Lexington, MA 02421 Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on June 3, 2025 Vote in Advance of the Meeting Vote by June 2, 2025 11:59 PM ET Visit www.ProxyVote.com Vote in Person at the Meeting* Date: June 3, 2025 Time: 11:00 AM ET

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V71954-P31358 Voting Items Board Recommends THIS IS NOT A VOTABLE BALLOT This is an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. Please follow the instructions on the reverse side to vote these important matters. 1. To elect each of the following nominees to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified. For Nominees: 01) Grace E. Colón, Ph.D. 02) Catherine J. Mackey, Ph.D. 03) Glenn Pierce, M.D., Ph.D. 04) George Scangos, Ph.D. 2. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers. For 3. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. For 4. To approve the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. For 5. To approve the Voyager Therapeutics, Inc. Amended and Restated 2015 Employee Stock Purchase Plan. For NOTE: The Board of Directors may also transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof.

    Get the next $VYGR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VYGR

    DatePrice TargetRatingAnalyst
    1/10/2025Overweight
    Cantor Fitzgerald
    12/2/2024$12.00Buy
    Citigroup
    11/29/2024$7.00 → $11.00Outperform
    Wedbush
    10/16/2024$15.00Outperform
    Leerink Partners
    3/26/2024$22.00Buy
    Guggenheim
    3/19/2024$30.00Buy
    H.C. Wainwright
    3/7/2024$16.00Buy
    Citigroup
    1/2/2024$14.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $VYGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Voyager Therapeutics

      Cantor Fitzgerald initiated coverage of Voyager Therapeutics with a rating of Overweight

      1/10/25 9:15:32 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Citigroup initiated coverage on Voyager Therapeutics with a new price target

      Citigroup initiated coverage of Voyager Therapeutics with a rating of Buy and set a new price target of $12.00

      12/2/24 7:04:18 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush resumed coverage on Voyager Therapeutics with a new price target

      Wedbush resumed coverage of Voyager Therapeutics with a rating of Outperform and set a new price target of $11.00 from $7.00 previously

      11/29/24 7:27:18 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

      LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. An on-demand webcast of the pre-recorded fireside chat will be available and may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com starting at 7:00 a.m. ET on June 17, 2025. The on-demand webcast will be archived on the Compan

      6/10/25 7:00:51 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

      - Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer's di

      3/31/25 7:00:47 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

      - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer's patients expected H2 2026 - LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2024 financial and operating results. "Over the past year, Voyager has significantly advanced our two wholly-

      3/11/25 4:01:00 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    SEC Filings

    See more
    • SEC Form S-8 filed by Voyager Therapeutics Inc.

      S-8 - Voyager Therapeutics, Inc. (0001640266) (Filer)

      6/9/25 4:07:18 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Voyager Therapeutics, Inc. (0001640266) (Filer)

      6/5/25 4:13:46 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Voyager Therapeutics Inc.

      SCHEDULE 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

      5/15/25 3:22:45 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care